Background: We developed preference-based and summated scale scoring for the Testing Morbidities Index (TMI) classification, which addresses short-term effects on quality of life from diagnostic testing before, during, and after testing procedures. Methods: The two TMI preference functions use multiattribute value techniques; one is patient-based and the other has a societal perspective, informed by 206 breast biopsy patients and 466 (societal) subjects. Because of a lack of standard short-term methods for this application, we used the visual analog scale (VAS). Waiting tradeoff (WTO) tolls provided an additional option for linear transformation of the TMI. We randomized participants to 1 of 3 surveys: The first derived weights for generic testing morbidity attributes and levels of severity with the VAS; a second developed VAS values and WTO tolls for linear transformation of the TMI to a ''dead-healthy'' scale; the third addressed initial validation in a specific test (breast biopsy). The initial validation
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Appendix A addresses the calculation of a WTO toll and relationship of the WTO to temporary TTO as a variant of a chained method. Among generic indexes, only the EQ-5D has been used for testing. 18, 19 A known limitation in using the EQ-5D in short-term health states is its pronounced ceiling effect. 20 An index capable of measuring the effects of any diagnostic test would improve HrQoL assessment. A parsimonious, face-valid classification of diagnostic testing domains has been described, now called the Testing Morbidities Index (TMI). 21 The TMI consists of 7 attributes for physical and mental aspects of HrQoL prior, during, and after testing ( Table 1) . Prior psychometric analysis suggests content and construct validity of the 7 TMI items. 21 The TMI might therefore be applicable in preference-based or summated scale versions (Appendix B), and scaling alternatives could allow varied applications. A summated scale may be more responsive than a preferencebased instrument. 22, 23 We describe derivation of patient and societal preference functions for the TMI by adapting multiattribute value methods. 3, 24, 25 We applied the TMI initially in breast biopsy, comparing it with direct VAS and WTO. Secondary goals included exploration of model specification and alternative scoring as a summated scale.
METHODS

Ethics
The Partners Healthcare/Massachusetts General Hospital Institutional Review Board (#2005P002377) approved the study.
Overview of Participants and Rationale
The societal perspective is often preferred for HrQoL data in cost-effectiveness analysis, but its advantages over a patient perspective remain controversial. 1, 26, 27 An instrument using the patient perspective is the Patient-Oriented Prostate Utility Scale (PORPUS). 25 The patient and societal perspectives are both relevant for the TMI, since either view can affect testing adherence. Any reference to ''subjects'' or ''community'' refers to our societal sample. ''Participants'' refers to patients and subjects. Both societal and patient groups had survey items assessing numeracy and literacy and provided socioeconomic data ( Table 2) . 28, 29 Patient Perspective Group. To obtain an estimate of preferences in patients who recently experienced a test, we recruited English-and Spanish-speaking women who had breast biopsy. Demographics of patients seen in our breast center are representative of our US Census region. 30 On the date of biopsy, a study coordinator provided patients with survey materials. A VAS feeling thermometer was included with a letter that introduced the study and described assessments. Telephone interviews occurred within 3 days after biopsy (average) and before results were known, allowing patients to review the survey and focus on the testing experience without the influence of knowing the biopsy results. Mixed-mode survey approaches including telephone have been used successfully. [15] [16] [17] 31 Subject (Societal) Perspective Group. We used our patient registry, which includes more than 1.5 million people. 32 Eligible subjects were ages 21-80, were of either gender, and spoke English or Spanish. We excluded those with previous breast biopsy and other recent testing. We drew random samples within strata of age group, gender, and race/ethnicity on a quarterly basis to ensure subject assessment in the approximate time frame of patient accrual. We mailed cover letters and survey instruments to subjects and followed up with telephone interviews.
Modeling Approach: Multiattribute Value Theory
Utility index development uses either multiattribute utility, multiattribute value theory 3, 24 (MAUT/ MAVT) or multiple regression. 4, 5 Recent work from the National Health Measurement Study shows reliability coefficients for the MAUT/MAVT-based Health Utilities Index Mark 2 and 3 (HUI2/3) 33 that are similar to or better than regression-based indexes. Larger sample sizes are generally needed for regression models compared with MAUT, 25, 34 and we planned to develop 2 separate value functions to capture the patient and societal perspective, requiring 2 modeling groups. Finally, ceiling or floor effects have been substantial in some regression models, which might exacerbate the already likely potential for such problems in the TMI, regardless of method. 35, 36 Given these issues, and because we were not assessing risky outcomes, we used MAVT.
MAVT extends utility theory to explicit multiple HrQoL domains or attributes. 37, 38 The HUI2/3 is the most widely known MAUT/MAVT-based index. The HUI instruments have the multiplicative form, shown in Equation 1 in Table 3 . The details of MAVT calculations are discussed in Appendix C.
Modeling Groups Overview
Our approach had 3 main goals: 1) derive weights for the TMI classification and attributes, 2) derive preferences to enable rescaling of the TMI multiattribute valuation model on a ''dead-healthy'' scale, and 3) collect data for a first estimate of validation. To accomplish these tasks, 3 survey groups were set up identically for patients and subjects with randomized group assignment. For the first goal, an ''attribute valuation group'' valued the TMI attributes and their levels considering the effects of testing situations in general. For the second goal, an ''index scaling group'' valued the best and worst possible TMI health states for rescaling the index. Based on pilot studies, assessments for the first and second goals used a mix of disvalue and value perspectives. These differences required reconciliation with Equation 2 as shown in Figure 1 and Table 3 . Calculations used software modified from a prior application. 39 We addressed the third goal with a ''validation group'' comparing the TMI to directly elicited WTO and VAS, using breast biopsy as a first model test. Patient sample sizes were based on prior published data for WTO, 15 given its greater variability than VAS. Societal group sizes were based on group preferences likely having a standard deviation 1.5 times greater than patients. 40 The attribute valuation and index scaling groups were given graphics and text descriptions of tests of varying invasiveness (colonoscopy, phlebotomy, breast biopsy, and chest radiography). The validation group received the breast biopsy description.
Attribute Valuation Group: Attribute Levels, Weights, and Scaling Constant TMI Attribute Levels. Participants assigned a value to these levels, bearing in mind the likely impact of varying the level of each attribute when considering any (or many possible) diagnostic tests, assuming normal status of other attributes. Participants were presented with 5 levels within each attribute using a disvalue framework, where ''none'' was given a default value equaling 0 (no disvalue) and ''extreme'' a default value equaling 100 (Attribute Levels in Figure 1 ), later converted to a 0-1.0 scale. Participants gave their own VAS values for the ''mild,'' ''moderate,'' and ''severe'' levels 24, 25 ( Table 1) .
TMI Attribute Weights (k j ) and Scaling Constant (K) from Equation 1. Participants rank-ordered attributes by importance in a first, warm-up step. Assignment of weights (see Attribute Weights in Figure 1) was adapted from a combination of MAVT techniques. 38 Participants assigned 10 points to the least important attribute, and points greater than 10 to all others using ratios, by relative importance (importance weights) in this second step. We obtained the VAS value for the ''corner state'' of the most important attribute in our third step. A corner state in a disvalue framework is a health state where an attribute is at its worst level, with all other attributes at their best (all other attributes assumed to be normal or disutility of zero). The corner state defines an attribute's weight (k j ). We used the one corner state with the importance weights to solve for other corner states (k j ) in the final step to minimize burden, instead of directly obtaining all corner states. VAS valued the corner states with scale anchors of ''best imaginable health state'' and ''worst imaginable health state'' 4 at values of 100 and 0, respectively, thus serving as a value framework, requiring reconciliation to disvalue model terms like the levels ( Figure 1 and Equation 2 in Table 3 ). Using s j to denote the importance weight of the jth attribute and the most important attribute corner state preference as v (1) , s j is a ''relative'' v (j) . 38 The ratio of s j /s i is approximately equal to the ratio of v (j) /v (i) . Since v (1) is obtained directly and
the other attribute weights were derived, thus
The scaling constant K is iteratively calculated from the weights and Equation 1 as in Appendix C. Therefore, the TMI model developed variables in disvalue terms, and then conversion to a value function occurred (Equation 2) in anticipation of transformation to a scale of ''dead'' to ''perfect health'' ( Figure 1 ).
Index Scaling Group: Derivation of TMI Rescaling Preferences
Because attribute valuation groups provided patient and societal TMI models on a ''worst'' to Notation and formulas for multiplicative multiattribute disvalue and value functions (Equations 1 and 2; see also Appendix C): vðxÞ = multiattribute disvalue function for a health state x. vðxÞ = multiattribute value function for x. v j ðx j Þ = single attribute disvalue function for an attribute j. K = global scaling constant for a value/disvalue function. k j = scale weight for an attribute j.
= disvalue level in subject or patient function, first attribute. K s , K p = global scaling constants for subject or patient models using Equation 1; K s = 0.27, K p = 0.03. k s , k p = calculated attribute weight, subject function or patient function in Equation 1.
''best'' 0-1.0 scale (called ''final TMI value models'' in Figure 1 ), conversion to a ''dead'' to ''perfect health'' scale required linear transformation using preferences for the best (TMIbest) and worst (TMIworst) possible TMI states obtained from the index scaling group. We elicited VAS values for TMIbest and TMIworst, and because of a lack of applicable standard choice-based measures, we also used WTO tolls.
VAS Valuation. The TMIworst multiattribute health state summarized a hypothetical test with all worst levels in all attributes using the TMI classification language. Each participant chose TMIworst as valued greater than, equal to, or worse than dead. If ''equal to dead'' was chosen, then the individual was classified as operating on a scale where 0 equals ''dead'' and 100 equals ''perfect health.'' If TMIworst was valued ''greater than dead'' on the VAS, then on the VAS scale, again 0 equals ''dead,'' and TMIworst valuation was done accordingly. If TMIworst was considered ''worse than dead,'' then ''dead'' was valued above TMIworst on a 0-100 (''perfect health'') VAS. Subsequent linear transformation of TMIworst in this latter group followed the work of Patrick and others, 41 where the worst state, V(x), is rescaled as
allowing negative preferences, with 21.0 the lowest allowed value. Group trimmed means for TMIworst were weighted by prevalence of those valuing it ''greater than or equal to dead'' v. those valuing it ''worse than dead,'' similar to the HUI3. 3, 42 The TMIbest state was valued similarly to TMIworst, using a multiattribute TMI scenario with all best levels. For TMIbest VAS valuation, the top anchor was ''perfect health'' and the bottom ''worst imaginable state'' or ''dead,'' depending on the prior assessment of TMIworst. WTO Valuation. The WTO derives a qualityadjusted life year (QALY) toll estimate by defining an indifference point between waiting for results of a hypothetical ''ideal'' test (brief, with no risk or pain) and treatment and having an actual, potentially noxious test where results and treatment are available immediately. [15] [16] [17] Waiting time was quality-adjusted by baseline and test-related anxiety preferences, requiring multiplication by 0.2 (Appendix A). To minimize anchoring bias, initial waiting time offers for TMIworst were randomized between 2, 4, 6, and 8 weeks. We offered 1 day if the participant declined the initial offer, and the assessment stopped if the individual declined 1 day (assumed indifference point of 0.5 day). Otherwise, bisection of the interval between the initial offer and 1 day occurred until indifference, unless the initial offer was accepted. In that case, 2-week intervals were added until a ''no'' response, followed by bisection to indifference. 15 TMIbest was similarly valued.
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Validation Groups A and B: Comparing the TMI with Direct Preferences
Subjects and patients provided preferences for breast biopsy with direct VAS, direct WTO, and TMI items. For subjects, assessments used slightly altered hypothetical language (e.g., for the TMI pain item during a test, ''How much pain or discomfort do you think you would experience?'' instead of ''How much . did you experience?''). 21 Group A had VAS anchors of ''dead'' and ''perfect health'' with sample size assumptions similar to the attribute valuation and index scaling groups, while Group B had direct VAS anchors of ''worst'' and ''best imaginable health state.'' These groups were developed due to bias concerns when ''dead'' was the lower scale anchor in patients. 43 Group B began early in the study, with sample sizes based on interim data.
Statistical and Other Modeling Considerations
Descriptive Statistics for Modeling and Agreement. We used 3 methods from HUI development. 3, 24, 40 First, a ''person mean'' was used, where instead of computing individual participants' indexes, overall means for each variable (weights for k j variables, level values, and TMIbest/TMIworst preferences) were obtained. The constant K and TMI model were subsequently calculated (Appendix C). Second, VAS data for model development were 10% trimmed means (Table 3) ; 10% trimmed means have also been advocated in the statistical literature. 44 Third, mean absolute difference (MAD) and overall standard deviation (OSD) calculations compared agreement of direct VAS or WTO with the VAS or WTO-scaled TMI ( Table 4 , Appendix C). The OSD is similar to a root mean square error calculation used in the PORPUS, 25 except that like the HUI3 formula, our OSD used trimmed means of direct measures instead of arithmetic means. For additional measures of agreement, mountain plots and Pearson correlations were calculated, supplemented with Spearman correlations.
Given no standards for analyzing WTO descriptive statistics, we calculated arithmetic, 5% and 10% trimmed means for the TMIworst and TMIbest values (Appendix C), and both of these trimmed means served to rescale the TMI calculations to WTO. We calculated arithmetic and 10% trimmed means for the direct WTO tolls ( The TMI as a Summated Scale and Further Exploration of the TMI Model. Appendix B explores psychometric evidence and scoring of the TMI as a summated scale. In Appendix C, we include details on MAVT, additive v. multiplicative models, patient and subject model differences, ''worse than dead'' states, scaling parameters, and agreement formulas. Appendix D summarizes TMI results by quartile of VAS scores. A downloadable version of the TMI models supporting calculations is available from the authors' Web site at http://www.mghita.org/TMIv1_1_0.xls.
RESULTS
Patients and Subjects: Demographics and Response Rates
Twelve-hundred eighty-five individuals participated (394 patients, 891 subjects, Table 2 ). Patient response rate was 93% among those contacted during the period of eligibility and 79% among patients at the time of biopsy. Subject response rate was 55%.
Ten incomplete surveys were noted, with 4 yielding usable data ( Table 2 ). Population demographics were consistent with our US Census region. 30 On average, 4.6% said they could not perform certain health communications tasks; 73.3% and 77.2% answered numeracy questions correctly on probability and percentage of risk, respectively (Table 2) ; a ''highly educated'' sample in the literature correctly answered them 78% and 84% of the time. 28 No numeracy issues were suggested from interviews or overall results.
Attribute Valuation and Index Rescaling Groups
Participants indicated no difficulties in valuing corner states. Comparison of rank ordering of attribute importance and ratio importance weights showed significant Spearman correlations in the patient group (mean rho: -0.69) and the subjects (mean rho: -0.73) (range across groups: 20.58 to -0.83, all P \ 0.001). The patient model result was weakly multiplicative, with K p = 0.03 (Table 3) , and is solvable with the additive equation (Appendix C: Equation 1C ). Attribute final scale weights for patient or societal models were between 0.12 and 0.20, excluding the attribute ''embarrassment.'' The societal model was somewhat more multiplicative in structure (K s = 0.27, Table 3 , Appendix C).
Similar to the PORPUS attribute level valuations, 25 our least important attribute, embarrassment, showed less mean disutility in more severe levels. There was acceptable to good internal consistency of the TMI items in the validation group (Appendix B).
Index scaling group societal/patient values (Appendix C) with VAS showed 10% trimmed mean TMIworst values at 0.31/0.39 and TMIbest at 0.90/ 0.93, respectively. Thirteen subjects and 3 patients contributed ''worse than dead'' values to the TMIworst weighted results. Allowing health states ''worse than dead'' with VAS did not affect the models (Appendix C). WTO waiting time values for TMIworst were more variable, unlike TMIbest WTO results.
Validation Groups
The 4 survey groups were kept separate for comparisons ( Table 4 ), because of scale anchors for VAS and TMI VAS , and to keep those with identical surveys and perspectives (patient or subject) together. Patient groups trended similarly, as did subject groups. Direct VAS for biopsy ( Table 4 ) indicated greater disutility in subjects (0.64-0.70 trimmed mean) compared with patients (0.79), which was significant. Table 4 shows Validation A subjects (n = 235) with 2 extreme outliers excluded from direct WTO tolls, who waited more than 6000 and 12,000 unadjusted days. The mean (standard deviation) WTO toll in quality-adjusted life days (QALDs) with these outliers excluded, as in the table, was 2.80 (3.84), as opposed to 19.24 (185.18) with them. Direct WTO showed a similar trend to VAS in its 10% trimmed mean values, with a greater toll in subject groups than patients had, but this difference was not significant.
The TMI models also showed significantly increased disutility in subjects v. patients (increased WTO tolls and decreased VAS). Patient and subject groups trended similarly.
Agreement appeared better in patients than subjects overall, with MAD and OSD measures smaller in patients with the VAS and WTO scaled models. Similarly, mountain plots ( Figure 2 ) showed less bias in patients. However, both groups showed long tails in the distributions indicating suboptimal agreement, usually due to lower VAS values. There was a marked tendency for participants to anchor on 0.05-0.1 increments on the 0-1.0 VAS scale (Figure 3 ). TMI WTO results in Table 4 for validation group A exclude the 2 subject outliers. Small differences in MAD or OSD occurred when these outliers were included (range: 0.02-0.07 QALD).
There were moderate to strong 45, 46 Pearson correlation coefficients between direct VAS and TMI VAS across validation group patients and subjects (r = 0.45-0.62, all P \ 0.0001). For direct WTO v. TMI WTO , 1 group (B patients) was significant at the 0.05 level (r = 0.31, P = 0.0039). Group A and B subjects showed weak Spearman correlations between WTO and TMI WTO (rho = 0.16-0.17, P = 0.0095-0.02).
There was no TMI floor effect. The ceiling effect in Group A and B patients and subjects was 6%, 1.7%, 3.4%, and 0.5%, respectively.
DISCUSSION
We applied preference weights to a health classification for measuring short-term HrQoL related to diagnostic testing. The TMI has 5 different scaling alternatives: 1) a patient perspective TMI VAS on a ''dead-healthy'' scale; 2) a patient TMI WTO where the ''worst-best'' VAS model is rescaled with quality-adjusted WTO data for the best and worst model states; 3) and 4) the 2 prior options from the societal perspective; and 5) a summated scale version. Therefore, the TMI could find applications in patient or subject groups or where preferences are not needed.
We followed the general techniques used in the development of other MAUT-based indexes, where a health classification is valued on a variant of a ''best'' to ''worst'' scale, followed by linear transformation to a ''dead'' to ''perfect health'' scale. 3, 25 However, in development of the TMI, the choices made had strengths and limitations. We will discuss our choices and results in 6 categories below.
Multiattribute Value Theory
As cited in the Methods section, MAVT provided multiple advantages. Temporal separation of TMI attributes (before, during, after) likely aided in mutual preferential independence (called ''structural independence'' by the HUI Group 42 ), and we had successful corner state valuations. However, in order that a MAVT-based instrument is generic, attributes must be valued in a generic sense. Thus, participants valued attributes considering the impact of any test experience. This method is similar to a typical generic index where a health state is valued with varying levels of the attributes, not otherwise specified as to disease or other context. Such an exercise involves a significant change in focus for some people, although preference assessments in general are not usual activities for most of us. To what degree such assessments are truly understandable in a generic context has not been explored, but the fact that existing indexes tend to correlate well with one another suggests meaningfulness of their constructs. 47 Structural independence in MAVT has long been a concern and has partially motivated the development of statistical modeling for indexes. 5 Such independence assumes that attributes can be valued independent of one another and that corner states can be valued and serve as attribute weights. Nonetheless, development of independent attributes is often challenging. Therefore, the plausibility of The median difference between TMI and VAS is represented by the curve peak and is very near zero in patients (-0.01). The subjects show a more negative bias, with the median difference at 20.06. Large negative tails reflecting lack of agreement are seen (left side of plot) due to low VAS values in both groups, greater in subjects. Positive tails, where VAS is greater than TMI, are also noted but are less notable than negative tails and are more prominent in subjects. (B) Mountain plots of Group B patients and subjects. Bias is greater in patients (median difference -0.045) than Group A and in subjects (20.14) . The mountain distribution is wider in subjects than patients, but both show wide tails, with negative tails more prominent. 
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A B Figure 3 (A) Cumulative frequency distributions: direct VAS across validation groups. As in Table 4 , the subjects gave lower VAS scores for biopsy than patients, but both groups tend to anchor on 0.05-0. corner states is a potential limitation to applying MAVT in any model.
Direct Measures
Although using the VAS is controversial, 43, 48 its validity has been advocated recently. 49 It is included in 2 widely used instruments; the Quality of Well Being Scale 6 and HUI2/3, in the latter transformed to a standard gamble (SG). 3, 24 In the HUI3, a 10% trimmed group mean for VAS as well as SG utilities reduced the influence of outliers on the mean estimate. In our use of the 10% trimmed mean VAS, we found expected trends, where temporary health states were valued as being low, but usually above dead. Even so, limited feasible direct measures created challenges. The VAS is most feasible, but with no standard choice-based measure to which VAS can be transformed, our choice was to use the WTO as an option for rescaling the index. Adding to these issues is the tendency for individuals to anchor on coarse VAS increments (0.05-0.10 on a 0-1.0 scale, Figure 3 ). Similar findings were noted by Raisch and others 50 in recent work in which a similar ''feeling thermometer'' VAS was used alongside the SF-6D and HUI2/3. Otherwise, we found no apparent trend by varying the VAS scale anchors in validation groups A v. B. This suggests that participants focused more on the scale rather than the anchors, which may be most relatable to a testing state.
The WTO avoids the infeasibility of usual choicebased measures in testing scenarios. Prior work has suggested evidence of WTO validity. [15] [16] [17] Although the WTO is conceptually equivalent to the chained temporary TTO 15 (Appendix A) , its open-ended scale could allow indefinite waiting. Furthermore, reasons for waiting may be complex. Given the WTO's relative novelty, there is no guidance as to how to handle outliers. We presented the TMI WTO where the initial model is rescaled with 5% or 10% trimmed means of TMIbest and TMIworst direct WTO values. Mean untrimmed direct WTO QALD tolls in our study were consistent with published values for breast biopsy, 15 and face-valid WTO wait times were found for TMIbest and TMIworst states (Appendix C), but trimmed mean estimates may be more meaningful. Although variability of the direct WTO was noted (Table 4) , the MAD and OSD for TMI WTO v. WTO at close to 1 QALD across groups was promising.
Agreement and Other Aspects of Performance
There was evidence of similar agreement of TMI-VAS with direct measures when compared with the original HUI2 validation study. 51 Specifically, the HUI2 MAD was 0.08 for its person-mean disvalue function 24 ; our VAS MAD was 0.07-0.10 in 3 out of 4 groups with 1 at 0.17. However, when the HUI2 multiattribute VAS disvalue function result was used to derive the multiattribute disutility function from the power curve calculation, the MAD was 0.15, thus close to our worst group at 0.17. Furthermore, the HUI2 OSD was 0.10 and 0.23 for the person mean disvalue function and the disutility function derived from the multiattribute disvalue function, and ours ranges over 0.08-0.19 for TMI VAS v. direct VAS. 24, 51 The HUI2 has had good reliability coefficients in recent literature. 33 These results are also encouraging since variability is likely greater in our scenario, where each participant's ex ante or ex post preference is being calculated. In contrast, identical marker states were valued ex ante by all HUI2 subjects.
Although our agreement results are no worse than HUI2 v. its VAS, disagreement is substantial in some individuals (Figure 2 ). Arnold and others 52 showed that agreement between direct measures and indexes is suboptimal. In many cases, the lack of agreement between indexes and direct measures might be explainable by the subject perspective of indexes as opposed to the patient perspective in direct assessment. However, Arnold also noted this bias when the perspective issue is not relevant-when ''hypothetical patients'' are giving their preferences. Findings of lack of agreement are also noted across indexes in the work of the National Health Measurement Study, which has shown that although utility indexes share constructs such as ''physical,'' ''psychosocial,'' and ''pain'' 53 and correlate with one another, 47 they are not interchangeable in terms of agreement. 54 Encouraging results came from our observations on ''worse than dead'' states and ceiling effects. Worse than dead states were not a substantive influence as expected. Ceiling effects were smaller than or comparable to the best performing generic indexes in this respect. EQ-5D ceiling effects range from 36% to 49%, the HUI2/3 from 4.5% to 15.4%, and SF-6D from 1.7% to 5.8%. 20, 33, 36 Patient and Subject Perspectives Patient group results were generally similar to one another, as were societal groups across measures (Table 4 ). Patient data in men are limited by the uncommon need for breast biopsy in men. Because men tend to value their HrQoL higher than do women, their inclusion could have caused an even greater difference between the patient and societal models. 55 The patient and societal models do appear substantively different (Appendix C), and patients valued quality-adjusted states higher than did subjects, consistent with prior literature. 1, 2, 56 Therefore, even though the modeling groups were valuing attributes of testing in a general context, and subjects had information on testing, the patient relative to subject difference persisted. Among reasons for this difference might be that patients valuing health states have a broader perspective of testing than do subjects, who may tend to focus on morbidity. 27 Mountain plot results ( Figure 2 ) may suggest that such assessments are more meaningful for patients, given less bias. The appropriate perspective in short-term assessments is unclear at this point, and given that everyone's perspective is relevant for testing adherence, continued evaluation of both points of view seems reasonable.
Respondent Burden and Attribute Valuation
The classic literature in MAVT provides help in decreasing burden. As von Winterfeldt and Edwards 38 noted, ''In principle it is possible to combine virtually any technique for single-attribute value or utility measurement with any weighting procedure and aggregation model.'' In our case, valuation of a single corner state with iterative calculations of other corner states by importance weights likely facilitated a consistent weighting structure in each person, while decreasing burden. Separate randomly chosen groups valued rescaling states (index scaling group) v. the attribute weights and levels (attribute valuation group), further decreasing burden.
However, the conceptual basis of attribute weighting presented challenges, given our burden concerns. Approaches that use importance of an attribute are listed in a complementary fashion with those that do not rely on importance (swing weights or corner states) in the MAVT literature. 38 Furthermore, adding to the confusion, a discussion of swing weighting may use the word ''importance'' in describing its method. 57 The main concern is potential conflating of importance and value by respondents. Thus, an attribute that has low weight could receive an inappropriately wide range of level values, similar to an attribute that is highly weighted. Although we chose to use importance weights to minimize the number of direct corner assessments, we found reasonable ranges of valued levels (mild to severe) given the resulting attribute weights. Referring to Table 3 , in subjects, the attribute with the highest weight had the greatest severe level value (pain during a test at 0.76). Most others fell in the middle with severe levels in the low 0.70s to high 0.60s and similar weights. Mental aspects after testing came next with a severe level of 0.63 and slightly less weight, and the lowest weight for embarrassment is consistent with a severe level of 0.57. In patients, the attributes with highest weights have higher severe levels of 0.75-0.77. The middle group has severe levels in the high 0.60s to low 0.70s (fear during and mental after test) and smaller weights. Embarrassment has a severe level of 0.50 and has a low weight. The one exception we see in patients is that for Pain Before the Test, where the severe level seems somewhat overvalued at a trimmed mean of 0.79, which would likely have minimal model effects.
Conceptualization of Testing Health States as Process Utility and Limitations of Classification
The conceptualization of the TMI is consistent with the WTO concept, since the disutility/disvalue of testing represents a toll on the process of medical care. 15, 17, 58 This approach is somewhat different from a typical HrQoL method, where specific times are traded off or evaluated under uncertainty. WTO scaling for TMI allows a toll on the testing experience deductible from quality-adjusted life expectancy (QALE). Furthermore, modelers can attach a desired time frame to the TMI VAS . If such short-term outcomes are not sensitive enough for typical cost-effectiveness analysis modeling scenarios, they may be useful for patient-centered or comparative effectiveness applications.
The classification system of the TMI may be limited by the response set used, since the degree of morbidity is generally ''none'' to ''extreme.'' However, the TMI principally addresses the domains of pain and fear/ anxiety, and these constructs are handled similarly in the standard indexes. We have tried to adjust for this situation by giving more context-specific description in the survey item stems. Furthermore, the classification is enhanced by these domains being sampled at 3 intervals in the testing sequence.
CONCLUSION
The TMI is a brief 7-item instrument for measuring short-term quality of life in testing from both societal and patient perspectives, with multiple potential scaling options. This study adds to the construct validity information in prior work on the TMI. 21 Planned evaluation includes assessment of test-retest reliability, responsiveness in testing scenarios compared with existing indexes, and evaluations over a range of test invasiveness.
APPENDIX A The Waiting Tradeoff
Multiple studies have compared more and less invasive testing methods with the WTO, including magnetic resonance angiography v. catheter angiography in peripheral and cerebrovascular disease 16, 17 and different modes of breast biopsy. 15 Results suggest the general validity of this approach, where greater tolls reflect greater disutility. Figure A1 shows t0 as the time a test begins and t1 as the time it ends; t2 is the time the individual is willing to wait to avoid the noxious test, obtained with a typical choice-based search pattern to indifference point. The waiting time (t2 -t1) is quality-adjusted by the difference between the utility for a relevant baseline health state (Ubase) and the utility of the relevant disease state (Ustate). Thus, in Figure A1 , the rectangle abcd reflects disutility (disvalue), and Disutility 5 ðt2 À t1Þ 3 ðUbase À UstateÞ:
In the case where there are clear clinical symptoms for Ustate that are attributable to the disease of interest, the waiting scenario is straightforward. For example, in peripheral vascular disease, a person may wait with symptoms of claudication to avoid having an angiogram by catheterization of a major artery. Waiting with symptoms is a realistic construct. Furthermore, utilities exist in the literature for vascular claudication (Ustate) as well as treated vascular disease (Ubase). 16 More problematic is the scenario where the patient is asymptomatic from the disease of interest. In such cases (e.g., breast biopsy for cancer or other screening), it has been noted that the individual does have an overt disease state-anxiety, which affects health during the events surrounding testing or screening. 8 TTO values for test-related and baseline anxiety were obtained previously for qualityadjustment of the waiting time in breast biopsy, 15 and they were influential in quality adjustment of the WTO for generic use in rescaling the TMI. This prior work showed a mean difference between TTO preferences for test-related and baseline anxiety of 0.17, which was used for quality-adjustment. 15 However, larger studies have shown a difference between the mean utility of anxiety disorders 59 and national baseline norms (mean of male and female norms of 40-49 age group) of 0.195. 55 Therefore, taking these data sources into consideration for a reasonable estimate, waiting times from the initial TMI WTO result and direct WTO assessments in the validation group were quality-adjusted by multiplying them by 0.2 as in the disutility equation above. The final qualityadjusted WTO result is usable as a toll on qualityadjusted life expectancy in economic models. We recognize, however, that this difference between anxiety and baseline may be conservative, given the work of others. 60 Figure A2 shows that conceptually, the WTO is a variant of temporary TTO, as has been described. 15 Ubase (utility of baseline), Ustate (utility of the prevailing health state-intermediate in position here), and Utest (utility for the test health state) in the WTO are similar to states we could call Ubest (utility for best health state), Uint (utility for intermediate state), and Uworst (utility for the worst health state) in temporary TTO. The main difference in WTO v. TTO lies in which health state in the chain is varied. In temporary TTO used in a testing context, the actual testing health state length (t1) is varied (Uworst), while in WTO, the Ustate health state (t2) is varied during assessment (Uint in temporary TTO). Varying the length of t1 is unrealistic, while varying t2 is reasonable, representing waiting with symptoms.
Like other adapted TTO techniques, there is a likelihood of proportional tradeoff violation in the WTO. 10 Other WTO limitations include the potential complexity of waiting as a construct and possible indefinite waiting. To create reasonable bounds on WTO waiting in future applications, the current study data for the TMIworst and TMIbest states may be applicable. Multiple WTO measures of the best and worst testing states are now available, given the arithmetic, 5%, and 10% trimmed means in Appendix C.
APPENDIX B
The Psychometric TMI A prior study showed evidence of construct and content validity of the TMI health classification. 21 Principal components analysis in that study also showed that the TMI items loaded strongly with items from an existing summated scale profile addressing the adherence barriers of various colorectal screening technologies. 9 This expected linkage with barriers was present in patients experienced with colorectal cancer screening as well as societal participants.
In the current data set, internal consistency of the TMI items was assessed using Cronbach's a statistics for the patient and societal validation group participants. A set of survey items should optimally have a ! 0.70 for use in research group comparisons. 61 In the pooled TMI patient groups (n = 188), a = 0.72, and in pooled societal groups (n = 425), a = 0.80.
The above lines of evidence taken together suggest that the TMI is applicable as a nonpreference summated scale. However, it is important to comment on differences in the aims of the conceptual models of utility indexes as opposed to many psychometric scales.
At first consideration, it would seem counterintuitive that a multiattribute value theory-based index could show internal consistency, since independence among attributes may decrease their correlation. From the MAVT perspective, a finding of internal consistency does not necessarily preclude structural independence of a group of MAVT-based attributes, because ''environmental correlation'' of attributes does not preclude their ''judgmental independence'' as noted by von Winterfeldt and Edwards. 62 In other words, a group of attributes may show statistical correlation attributable to circumstances of the application or the groups in which they are applied while still being viewed as independent for valuation by individuals.
From the psychometric perspective, internal consistency can vary with an instrument's applications, but conceptual frameworks are likely even more important. Utility indexes follow a more ''formative'' concept, because attributes and survey items together form a construct related to HRQoL. Attributes may vary independently and may be called ''causal'' variables. 63, 64 For example, in a generic preference index, if HrQoL decreases, it is not required that all attributes show disutility. Many psychometric instruments, in contrast, have items that have a ''reflective'' structure, where the items reflect the underlying HrQoL construct and so are more correlated, often called ''indicator'' variables or ''effect indicators.'' 64 For example, indicator variables for psychological distress (e.g., worrying thoughts, restlessness, irritability, etc.) would tend to trend together. Factor analysis and testing of internal consistency assume this reflective structure and may be indeterminate or confusing in formative models. Even so, such conceptual divisions are not always clear; some mixture of formative and reflective aspects may be present. A developer of the AQoL instrument noted these blurred conceptual boundaries and proposed that while development of the domains of a MAUT-based instrument should look to classical psychometrics, the combination of these same domains into an overall HrQoL concept should use the formative modeling of economics/decision analysis. 65 Since the developmental focus of the TMI was as a utility index, we expect that there could be many testing applications where independence aspects of the TMI are much more optimal than its internal consistency. The above concerns notwithstanding, Fayers 64 has noted that even for a set of formative/causal variables, a simple summated score will frequently be robust. Similarly, Tomlinson and others 25 and the PORPUS developers also provided summated scoring. With this in mind, we modified an equation from Tomlinson and others below to convert the 7-item TMI summated scale to a 0-100 scale, with 100 being the best possible score (best possible test). Each item has equal weight and the response is coded 1-5 in variable L i . The denominator value of 4 is the number of response categories (5 in all items) -1. Table 3 in the text is the MAVT version of a MAUT-based function. As is evident from comparison with Equation 1A below, MAUT and MAVT preferences use similar formalism. 24, 38 This appendix presents further details on the use of this and other equations related to it. If Equation 1 is used for a utility function (Equation 1A) , the notations are as follows: u j (x j ) is the single attribute utility function for an attribute (j), where 0 is the worst morbidity value possible and 1.0 is the best. The single attribute function reflects utility attached to each of the intermediate levels of function on a 0-1.0 scale. K is a global scaling constant that captures the preference relationships among attributes. k j is the weight applied to each attribute, representing its contribution in the overall utility function. p represents multiplication through all attributes j = 1 through n. 3, 37 Equation 1B is used for the iterative calculation of K, once the k j values are all known. In our case, after obtaining the group mean k j value for each attribute, K for patient and societal models was derived with Equation 1B using Newton's method. 66 If the sum of all k j is 6 ¼ 1.0, K is needed to scale the multiplicative function between 0 and 1.0. In such a case, attributes can only relate to one another as preference complements or substitutes, not both. 3 If attributes act as complements, the net increase in utility when both improve is greater than if they are substitutes. If all k j values sum to 1.0, a linear additive model is implied (K = 0), with no preference relationships among attributes (Equation 1C) .
where
uðxÞ 5 X n j 5 1
In health scenarios, a disutility (disvalue) model is generally more intuitive, where the absence of morbidity is equal to 0 on the utility scale and 1.0 is equal to the worst health state. Disutility assumptions have been used in multiple indexes. 3, 25 Accordingly, the k j weight for each attribute is equal to its corner state assessment, 3 where each attribute is valued at its worst possible level (1.0), with all other attributes assumed to be normal or disutility equal to 0. This approach becomes clear when Equation 1A is set as a disutility model (thus, u(x)) for a corner state. In such a case, all other attribute terms drop out (morbidity equal to 0) with disutility equal to k j for the one attribute at its corner state. Transformation to a utility (or value model, delineated by v(x)) using Equation 2 is typical: uðxÞ 5 1 À uðxÞ or; vðxÞ 5 1À vðxÞ (Equation 2 from main text).
MAVT-based indexes assume reasonable structural independence (mutual preferential independence) of the attributes; thus, any level of function in one attribute should be conceivable without regard to others. 3 A set of attributes lacking structural independence cannot generate plausible corner states. Such independence obviates the need for direct valuations of thousands of possible states. In the TMI, temporal separation of attributes ( 
Specification of Additive and Multiplicative Models: Overview
A Ruby script (v. 1.9.2) generated the 78,125 possible 7-element health state vectors in the TMI classification. Each vector provided input for Excel (Microsoft) to calculate the model result as well as differences between models. Visual Basic for Applications provided the output of the models in Excel 2010. Because all 7 TMI items use the 5-level response set, the best possible vector is 1111111 and the worst is 5555555. Given that our results showed a variably weak multiplicative model (Equation 1) in patients and subjects (Table 3) , we assessed the differences between our additive and multiplicative models in all possible vectors, as well as the patient v. societal multiplicative models. Specifically, for each possible health state vector, a MAUTbased additive and multiplicative model calculated preferences using the derived patient attribute weights, level values, scaling constant K for the multiplicative model, and TMIbest and TMIworst scaling values (Equation 1, Table 3 , and section below titled Model Scaling Parameters and Agreement Formulas). We restricted modeling comparisons to VAS, since VAS results are more meaningful to readers and the WTO has had limited use. The societal model comparisons were handled similarly. Histograms summarized the results. Similarly, we compared the output of patient and societal multiplicative models.
Additive versus multiplicative models: patients. Given a value of K p = 0.03 (Table 3) , it is expected that the additive and multiplicative solutions would be similar in patients. Almost all differences over the 78,125 possible health states are at or less than 0.01.
Additive versus multiplicative models: societal. Since K s = 0.27 in the societal model (Table 3) , more divergence is expected between the additive and multiplicative solutions, although this K value indicates the model is still not strongly multiplicative. Nonetheless, more than 25% of the vector value differences are at 0.02 or greater ( Figure C1 ). The minimal important difference (MID) for the TMI VAS would be helpful to estimate whether these differences between models are important. The TMI MID is not known by anchor-based approaches, but a preliminary estimate is conceivable with distributionbased methods. Others have noted that one-half the standard deviation (SD) of the instrument may approximate the MID 67, 68 in patient-reported outcomes instruments, and in preference-based instruments, 0.3SD has been proposed. 69 Using the preference-based TMI VAS version on a dead to healthy scale, our preliminary calculations below suggest that the MID may be from 0.02 to 0.04. This range is relevant to the societal model comparison above as well as the patient v. societal model comparison discussed below.
In considering the MID for the TMI, we found that in pooled breast biopsy patients (n = 188) and pooled societal subjects (n = 425), the standard deviation of the TMI VAS is 0.062 and 0.073, respectively. This gives a range of 0.018-0.022 for 0.3SD estimates across patients and subjects, and for 0.5SD estimates, Subject and patient MIDs are 0.031 and 0.033 using these standard deviation estimates and the Cronbach's a results from Appendix B for reliability.
However, as noted in Appendix B, Cronbach's a may be less appropriate in utility models. Test-retest reliability data, once available, may be more optimal for SEM estimates.
Patient v. Societal Modeling Perspective
Differences between the patient and societal multiplicative models appear substantive. The histogram ( Figure C2 ) shows most differences at 0.03 or greater.
Health States Worse than Dead
We had provided for the possibility of a worse than dead health state at 5555555, following usual practices in utility index construction. However, the TMI is unusual in its focus on short-term health states. Our interviews revealed worse than dead preferences for health state 5555555 in 3/103 patients and 13/232 subjects in the index scaling group. This result is in contrast to the HUI3, 42 where most subjects in a sample of 256 found the HUI3 worst state or ''pits'' to be worse than dead (233/256). We compared the preferences obtained in the validation group if we used the TMIworst state as originally calculated (allowing negative preferences) as opposed to censoring our 3patient and 13-subject TMIworst VAS assessments at 0 (no allowance for negative preferences). Table C1 shows that for the mean TMI score, there is a 0.01 difference in Validation A subjects and no mean difference in Validation B subjects, comparing models with and without negative preferences. There was a maximum difference in these models of 0.014 and 0.012 in A subjects and B subjects, respectively; values at the 0.01 level or greater only occurred in about 2.5% of each group. The patient groups showed no differences, since the mean value for TMIworst in patients remained at 0.39 with or without negative preferences. (Table C2) and Agreement Formulas Formulas for Table 4 comparisons in text (superscript letters h-m refer to Table 4 ). Mean absolute difference (MAD) and overall standard deviation Note: TMI = Testing Morbidities Index; VAS = visual analog scale. a. The TMIworst VAS scaling state at 5555555 (0-1.0 dead to healthy scale) from the index scaling group was calculated as a 10% trimmed mean. It was weighted by the prevalence of negative (worse than dead) preferences in 13 subjects (also a 10% trimmed mean), as noted in the text. TMIworst = 0.31 (under the heading Model Scaling Parameters and Agreement Formulas). TMI VAS results in subjects in Table 4 
Model Scaling Parameters
APPENDIX D Mean TMI by VAS Quartile
In addition to analyzing the correlation of direct VAS with the TMI VAS in the validation groups, we calculated the mean TMI score by quartile of VAS scores. Mean TMI score increases as VAS increases by quartile. as above) . a, 5, 10 = arithmetic mean, 5% trimmed mean, 10% trimmed mean. Conversion to ''dead to healthy'' scale (example using VAS patient function): v 5v VAS pb À VAS pw À Á 1 VAS pw , wherev = multiattribute value function as initially calculated on a ''best'' to ''worst'' scale and v = multiattribute value function on ''dead'' to ''healthy'' scale. 
